

## 04.呼吸器・炎症疾患治療分野

AstraZeneca has an active research programme to create novel treatments for diseases of the lungs and airways, such as asthma, chronic obstructive pulmonary disease (COPD) and other less prevalent disorders.

Many challenges remain in respiratory medicine, such as the development of novel drugs that interfere with the underlying disease processes, and the improvement of existing medications and delivery devices to simplify disease management for the patient.

Already a leader in the treatment of asthma, AstraZeneca is expanding its range by developing novel treatment in other areas of inflammatory diseases such as rheumatology.

### Key Areas of Partnering Interest

#### 呼吸器疾患治療分野

- **COPD and asthma**
  - **Advanced clinical programmes**
  - **Early stage alliances focussed on:**
    - Control of exacerbations – targets: inflammation, rhinovirus
    - Muscle wasting and dysfunction
    - Facilitating lung recovery – targets: inflammation, mucus destruction, remodelling
- **Novel inhalation approaches or other delivery concepts**

#### 炎症疾患治療分野

- **Rheumatology**
  - Agents in clinical development with patient efficacy data that are differentiated from marketed products, specifically in rheumatoid arthritis, systemic lupus erythematosus and scleroderma.
  - Early stage alliances in rheumatology